James Bahel Named Leidos Biomedical Research (SAI) Vice President Of Business Development

RESTON, Va., Sept. 29, 2014 /PRNewswire/ -- Leidos (NYSE: LDOS), a national security, health and engineering solutions company, announced that James Bahel has been appointed Vice President of Business Development for the Integrated Systems Group (ISG). Bahel will succeed Mike Stewart, who will continue his support in gaining internal efficiencies for ISG as Operations Manager.

Leidos logo.
ISG is comprised of over 3,200 professionals who bring deep domain knowledge, innovation, and responsiveness to help our nation face some of its most critical national security and intelligence challenges. ISG develops and delivers high-end intelligence and data solutions that support a wide range of customers in the United States and abroad. Cyber (Security, Operations and Commercial), Command and Control systems, Infrastructure Protection and Enterprise Information Systems are core competencies of ISG. In his role, Bahel will oversee all business development efforts for the ISG portfolio across this diverse customer base that encompasses the Intelligence Community, Department of Defense, Federal, Civil, commercial, and international customers.

Bahel has over 35 years of experience serving the intelligence community with tours in the military, as a civilian employee, and as a representative of private industry. Bahel also brings over 19 years of experience as both a military and civilian employee of the National Security Agency, serving in positions of increasing responsibility. Bahel has directed large systems engineering and technical assistance programs, provided regional profit and loss management for a national IRD corporation, and helped develop and grow business within signals intelligence, information security, and network engineering markets. Most recently he served as a senior Business Development representative of the Lockheed Martin Corporation, helping to secure over $1.2B in new business over a 24-month period. Bahel holds a bachelor of arts in Government and Politics from the University of Maryland College Park.

"James has had a very successful career and this is a great opportunity for him to take on the next level of challenges.  He is committed to the company's strategy to build our intelligence and national security business," said Leidos Group President Sam Gordy. "His strong leadership skills, ability to execute, and understanding of the intelligence market make him an exceptional addition to Leidos."

About Leidos
Leidos is a FORTUNE 500® science and technology solutions leader working to address some of the world's toughest challenges in national security, health and engineering. The Company's 21,000 employees support vital missions for our government and the commercial sector, develop innovative solutions to drive better outcomes and defend our Nation's digital and physical infrastructure from 'new world' threats. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $5.77 billion for its fiscal year ended January 31, 2014 after giving effect to the spin-off of the company's technical services and information technology business. For more information, visit www.Leidos.com.

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 31, 2014, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

Contact:

Melissa Koskovich

Jennifer Gephart    


(571) 526-6850

(571) 526-6852


[email protected]   

[email protected]

Logo - http://photos.prnewswire.com/prnh/20131120/PH20896LOGO

SOURCE Leidos

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.